Featured essay
CDMO biologics capacity and manufacturing bottlenecks: navigating capacity constraintsModern Catalyst The biologics manufacturing landscape in 2025 faces a structural mismatch: demand for monoclonal antibodies, cell therapies, and specialty biologics continues to outpace available GMP capacity, forcing procurement teams to rethink vendor selection criteria and…
Read full essay